{"filing":{"accession_number":"0000886163-26-000054","cik":"0000886163","ticker":"LGNYZ","company_name":"LIGAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"lgnd-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616326000054/lgnd-20260924.htm"},"events":[{"id":34725,"run_id":31970,"accession_number":"0000886163-26-000054","anchor_item_number":"7.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Ligand has entered into a financing agreement with AvenCell Therapeutics for up to $47 million, comprising $41 million in exchange for royalties on AvenCell's pipeline assets and $6 million in Series C equity financing. This is a material capital deployment and strategic investment that creates a new financial obligation and revenue stream for Ligand, but does not fit neatly into the specific categories of debt_issuance (Ligand is the investor, not the borrower), ma_activity (this is a royalty/financing arrangement rather than an acquisition or merger), or dilutive_issuance (Ligand is not issuing equity). The transaction is material to investors as it represents a significant allocation of Ligand's capital and establishes a new royalty-bearing asset in its portfolio.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38546,"accession_number":"0000886163-26-000054","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Ligand has entered into a financing agreement with AvenCell Therapeutics for up to $47 million, comprising $41 million in exchange for royalties on AvenCell's pipeline assets and $6 million in Series C equity financing. This is a material capital deployment and strategic investment that creates a new financial obligation and revenue stream for Ligand, but does not fit neatly into the specific categories of debt_issuance (Ligand is the investor, not the borrower), ma_activity (this is a royalty/financing arrangement rather than an acquisition or merger), or dilutive_issuance (Ligand is not issuing equity). The transaction is material to investors as it represents a significant allocation of Ligand's capital and establishes a new royalty-bearing asset in its portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:18:08.012748+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38546,"accession_number":"0000886163-26-000054","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Ligand has entered into a financing agreement with AvenCell Therapeutics for up to $47 million, comprising $41 million in exchange for royalties on AvenCell's pipeline assets and $6 million in Series C equity financing. This is a material capital deployment and strategic investment that creates a new financial obligation and revenue stream for Ligand, but does not fit neatly into the specific categories of debt_issuance (Ligand is the investor, not the borrower), ma_activity (this is a royalty/financing arrangement rather than an acquisition or merger), or dilutive_issuance (Ligand is not issuing equity). The transaction is material to investors as it represents a significant allocation of Ligand's capital and establishes a new royalty-bearing asset in its portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T12:18:08.012748+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-09-24"}]}